Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,328
  • Shares Outstanding, K 14,264
  • Annual Sales, $ 1,010 K
  • Annual Income, $ -7,640 K
  • 60-Month Beta 6.83
  • Price/Sales 62.88
  • Price/Cash Flow N/A
  • Price/Book 4.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +37.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.25 +7.29%
on 06/15/20
5.85 -22.05%
on 06/10/20
-0.10 (-2.15%)
since 06/09/20
3-Month
1.30 +250.77%
on 04/15/20
11.08 -58.84%
on 04/29/20
+2.93 (+179.75%)
since 04/09/20
52-Week
0.88 +418.18%
on 03/12/20
11.08 -58.84%
on 04/29/20
+1.24 (+37.35%)
since 07/09/19

Most Recent Stories

More News
Thinking about buying stock in Lakeland Industries, Capricor Therapeutics, T2 Biosystems, Callon Petroleum, or TOP Ships?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAKE, CAPR, TTOO, CPE, and TOPS.

CPE : 1.0600 (-6.19%)
CAPR : 4.56 (-1.94%)
LAKE : 25.07 (-2.79%)
Capricor to Participate in BIO Digital International Convention

Management to Host One-on-One Partnering Meetings

CAPR : 4.56 (-1.94%)
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020

Capricor Therapeutics ("Capricor") (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases,...

CAPR : 4.56 (-1.94%)
Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CAPR : 4.56 (-1.94%)
Capricor: 1Q Earnings Snapshot

BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $2.1 million in its first quarter.

CAPR : 4.56 (-1.94%)
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Duchenne Muscular Dystrophy Program

CAPR : 4.56 (-1.94%)
Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14

Capricor Therapeutics ("Capricor") (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases,...

CAPR : 4.56 (-1.94%)
Thinking about buying stock in Capricor Therapeutics, Waitr, Takeda Pharmaceutical, Sorrento Therapeutics, or Inovio Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, WTRH, TAK, SRNE, and INO.

CAPR : 4.56 (-1.94%)
INO : 23.27 (-0.81%)
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002

-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)-

CAPR : 4.56 (-1.94%)
Thinking about buying stock in Applied DNA Sciences, Agile Therapeutics, Canopy Growth Corp, Fluidigm Corp, or Capricor Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, AGRX, CGC, FLDM, and CAPR.

AGRX : 2.57 (-6.20%)
APDN : 8.14 (+1.43%)
CGC : 16.02 (-1.90%)
CAPR : 4.56 (-1.94%)
FLDM : 5.52 (-2.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CAPR with:

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

2nd Resistance Point 4.75
1st Resistance Point 4.65
Last Price 4.56
1st Support Level 4.46
2nd Support Level 4.37

See More

52-Week High 11.08
Fibonacci 61.8% 7.18
Fibonacci 50% 5.98
Fibonacci 38.2% 4.78
Last Price 4.56
52-Week Low 0.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar